Alimera Sciences — Technical Presentation (February 2011)
21 slides from Alimera Sciences's technical presentation, Feb 3, 2011
Slide 1: Selected Data from the FAME Study Webcast
Alimera Sciences, Inc. Selected Data from the FAME Study Webcast February 3, 2011 1
Slide 2: ILUVIEN Demographics
ILUVIEN Demographics 2
Slide 3: Patient Disposition
Patient Disposition Patient Disposition AE, adverse event; FAc, fluocinolone acetonide. 3
Slide 4: Study, Laser, and Off-Protocol Treatments
Study, Laser, and Off-Protocol Treatments Off-Protocol Treatments Off-Protocol Treatments 4
Slide 5: ILUVIEN Efficacy
ILUVIEN Efficacy 5
Slide 6: FAME Study Primary Variable
FAME Study Variable Primary Variable: Difference between treatment and control groups in percentage of patients with improved BCVA from baseline of 15 or more letters on the ETDRS eye chart 6 BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; FAME, Fluocinolone Ac
Slide 7: Trial A Full Analysis Set
^15 Letter Increase in BCVA Full Analysis Set - Trial A Full Analysis Set - Trial A Full Analysis Set - Trial A 7
Slide 8: Trial A Full Analysis Set
^15 Letter Increase in BCVA Full Analysis Set - Trial A Full Analysis Set - Trial A Full Analysis Set - Trial A 8
Slide 9: Trial B Full Analysis Set
^15 Letter Increase in BCVA Full Analysis Set - Trial B Full Analysis Set - Trial B Full Analysis Set - Trial B 9
Slide 10: Trial B Full Analysis Set
^15 Letter Increase in BCVA Full Analysis Set - Trial B Full Analysis Set - Trial B Full Analysis Set - Trial B 10
Slide 11: Trials A & B Combined Full Analysis Set
^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined 11
Slide 12: Trials A & B Combined Full Analysis Set
^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined 12
Slide 13: Observed Cases - Trials A & B Combined
^15 Letter Increase in BCVA Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined 13
Slide 14: Observed Cases - Trials A & B Combined
^15 Letter Increase in BCVA Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined 14
Slide 15: ILUVIEN By Lens Status at Baseline
^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline 15
Slide 16: ILUVIEN By Lens Status at Baseline
^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline 16
Slide 17: ILUVIEN Safety
ILUVIEN Safety 17
Slide 18: Cataract Side Effects
Cataract Side Effects Phakic Patients at Baseline Only Phakic Patients at Baseline Only Phakic Patients at Baseline Only 18
Slide 19: IOP Related Side Effects
IOP Related Side Effects IOP Related Side Effects 19
Slide 20: Additional Data and Analysis
Additional Data and Analysis Additional data and analysis of the FAME Study will be presented by Peter Campochiaro, M.D., on February 12, 2011, at 1:40 p.m. at the Angiogenesis, Exudation and Degeneration 2011 Meeting in the Mandarin Oriental Hotel, Miami, FL. 20
Slide 21: Selected Data from the FAME Study Webcast
Alimera Sciences, Inc. Selected Data from the FAME Study Webcast February 3, 2011 21
Alimera Sciences — Technical Presentation (February 2011) on 6ix